A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Pathology

• Publication date

  2004-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/path.1563PMID 15141374
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

  2004cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• Noninvasive and Invasive Micropapillary (Low-Grade) Serous Carcinoma of the Ovary: A Clinicopathologic Analysis of 135 Cases

  2003influential reference
• Diverse tumorigenic pathways in ovarian serous carcinoma.

  2002cited by this paper
• Molecular pathology of endometrial hyperplasia and carcinoma.

  2001cited by this paper
• Precursor lesions of ovarian epithelial malignancy

  2001cited by this paper
• Serous tumors of low malignant potential of the ovary-molecular pathology: part 2

  2001cited by this paper
• The Raf/MEK/ERK pathway: new concepts of activation

  2001cited by this paper
• K‐ras mutations in mucinous ovarian tumors

  1997cited by this paper
• Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors.

  1996cited by this paper
• Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.

  1996cited by this paper
• p53 protein expression in putative precursor lesions of epithelial ovarian cancer

  1995cited by this paper
• Update on early ovarian cancer and cancer developing in benign ovarian tumors

  1995cited by this paper
• Early de novo ovarian carcinoma. A study of fourteen cases

  1994cited by this paper
• Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma.

  1992cited by this paper

• Molecular Diagnostics in Ovarian Cancer: Position Statement of the Interregional Organization of Molecular Geneticists in Oncology and Oncohematology

  2025cites this paper
• The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers

  2021cites this paper
• Potential Role of KRAS and BRAF in Epithelial Ovarian Cancer

  2021cites this paper
• Low-grade Serous Carcinoma Arising in Inguinal Nodal Endosalpingiosis: Report of 2 Cases and Literature Review.

  2020cites this paper
• Cx43 and AKAP95 regulate G1/S conversion by competitively binding to cyclin E1/E2 in lung cancer cells

  2020cites this paper
• Establishment and characterisation of tumour-bearing mouse models for evaluation of biodistribution of a radiopharmaceutical

  2019cites this paper
• CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

  2018influential citation
• High‐grade serous carcinoma of tubo‐ovarian origin: recent developments

  2017cites this paper
• Concurrent high-grade serous carcinoma and borderline tumor demonstrating different chemo-sensitivity

  2017cites this paper
• Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers

  2017cites this paper
• Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.

  2016cites this paper
• Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria

  2016cites this paper
• Exploiting synthetic lethality in ovarian cancer

  2016cites this paper
• Combined serous carcinoma and neuroendocrine carcinoma of the fallopian tube.

  2015cites this paper
• Serous Tubal Intraepithelial Carcinoma (STIC)-like Lesions Arising in Ovarian Serous Cystadenofibroma: Report of 2 Cases.

  2015cites this paper
• Ovarian Cancer from Anatomy to Functional Imaging

  2015cites this paper
• miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.

  2015cites this paper
• Giant inflammatory polyposis with Crohn disease-like colitis.

  2015cites this paper
• Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

  2015cites this paper
• Overview of Epithelial Ovarian Carcinoma (EOC): Pathogenesis and General Considerations

  2014cites this paper
• Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma

  2014cites this paper
• The development of intratumoral heterogeneity in ovarian tumors: role of cancer stem cells in disease progression

  2014influential citation
• Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer

  2014cites this paper
• Ovarian borderline tumours: a review with comparison of serous and mucinous types

  2014cites this paper
• Functional analysis of low-moderate risk susceptibility genes emerging from pathway based approaches and genome wide association studies in epithelial ovarian cancer

  2013cites this paper
• AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation

  2013cites this paper
• BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer

  2013cites this paper
• Ovarian cancer

  2013cites this paper
• Ovarian cancer as a genetic disease.

  2013cites this paper
• Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

  2013cites this paper
• Low-Grade Ovarian Serous Neoplasms (Low-Grade Serous Carcinoma and Serous Borderline Tumor) Associated With High-Grade Serous Carcinoma or Undifferentiated Carcinoma: Report of a Series of Cases of an Unusual Phenomenon

  2012cites this paper
• Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development

  2012cites this paper
• Synergistic interactions of targeted therapy within signal transduction pathways

  2012cites this paper
• The mutational profile of sporadic epithelial ovarian carcinoma.

  2011cites this paper
• Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.

  2011cites this paper
• Ovarian borderline tumours: a review with emphasis on controversial areas

  2011cites this paper
• Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors

  2011influential citation
• Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas

  2011cites this paper
• Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

  2011cites this paper
• Ovarian cancer: predictors of early-stage diagnosis

  2010cites this paper
• The pathology of and controversial aspects of ovarian borderline tumours

  2010cites this paper
• Expression of the Retinoblastoma-related Gene Rb2/p130 in the Pathogenesis of Serous Carcinoma of the Ovary

  2010cites this paper
• Genetic Epidemiology of Mismatch Repair Deficiency in Ovarian Cancer

  2010cites this paper
• Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer.

  2010cites this paper
• Morphological and molecular basis of ovarian serous carcinoma

  2010cites this paper
• The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis

  2010cites this paper
• Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women

  2009cites this paper
• Recent advances in molecular gynaecological pathology

  2009cites this paper
• KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

  2009cites this paper
• Ovarian cancer: pathology, biology, and disease models.

  2009cites this paper
• Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer

  2009influential citation
• Increased p16 Expression in High-grade Serous and Undifferentiated Carcinoma Compared With Other Morphologic Types of Ovarian Carcinoma

  2009cites this paper
• Somatic Genetic Development in Epithelial Ovarian Cancer

  2009cites this paper
• MicroRNA Expression Profiles in Serous Ovarian Carcinoma

  2008cites this paper
• MicroRNAExpression Profiles in Serous Ovarian Carcinoma

  2008cites this paper
• Cigarette smoking and risk of epithelial ovarian cancer

  2008cites this paper
• Low-grade Serous Carcinoma of the Ovary Displaying a Macropapillary Pattern of Invasion

  2008cites this paper
• Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy

  2007cites this paper
• Epithelial Ovarian Cancer and Low Malignant Potential (LMP) Tumors Associated With a Lower Incidence of Second Primary Breast Cancer

  2007cites this paper
• An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma

  2007cites this paper
• High‐grade ovarian serous carcinoma exhibits significantly higher p16 expression than low‐grade serous carcinoma and serous borderline tumour

  2007cites this paper
• Chapter 3 – The Genetics of Breast and Gynecologic Cancers

  2007cites this paper
• My approach to and thoughts on the typing of ovarian carcinomas

  2007cites this paper
• Evaluation of the role of Helicobacter pylori as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration

  2006cites this paper
• Immunohistochemical and functional biomarkers of value in female genital tract lesions.

  2006cites this paper
• Benign Epithelial Ovarian Tumours—cancer Precursors or Markers for Ovarian Cancer Risk?

  2006cites this paper
• Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis

  2006cites this paper
• Germ line and somatic mutations of BRAF V599E in ovarian carcinoma

  2006cites this paper
• Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data.

  2006cites this paper
• Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.

  2006cites this paper
• Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.

  2006cites this paper
• p16 Expression in the Female Genital Tract and Its Value in Diagnosis

  2006cites this paper
• Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas

  2006cites this paper
• KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.

  2006cites this paper
• Differential expression of Protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples

  2005cites this paper
• Origins and molecular pathology of ovarian cancer

  2005cites this paper
• Optimisation of cDNA microarray tumour profiling and molecular analysis of epithelial ovarian cancer

  2005cites this paper
• An Immunohistochemical Comparison Between Low-Grade and High-Grade Ovarian Serous Carcinomas: Significantly Higher Expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in High-Grade Neoplasms

  2005cites this paper
• Tracing origin of serrated adenomas with BRAF and KRAS mutations

  2005cites this paper